Consistency of extended-release niacin/laropiprant effects on lp(a), apob, non-hdl-c, apo a1, and apob/apoa1 ratio across patient subgroups
American Journal of Cardiovascular Drugs, 05/30/2012
Bays HE et al. – ERN/LRPT produced lipid–altering efficacy on the parameters evaluated in four controlled studies; these effects were generally consistent across all examined subgroups. ERN/LRPT represents an effective and reliable therapeutic option for the treatment of dyslipidemia in a wide range of patient types.Methods
- In three of the studies, the randomized population included patients with primary hypercholesterolemia or mixed hyperlipidemia; in the remaining study, the population included patients with type 2 diabetes mellitus.
- The lipid–altering consistency of ERN/LRPT's efficacy was evaluated versus the pre–defined comparator (placebo or active control) among key subgroups of sex, race (White, non–White), region (US, ex–US), baseline age (<65 years, ≥65 years), use of statin therapy (yes, no), coronary heart disease (yes, no), risk status (low, multiple, high), and type of hyperlipidemia (primary hypercholesterolemia, mixed dyslipidemia), as well as across baseline LDL–C, HDL–C, and TG levels.
- The consistency of the treatment effects on lipoprotein(a).[Lp(a)], apolipoprotein B (ApoB), non–HDL–C, ApoA1, and ApoB/ApoA1 ratio was evaluated by examining treatment difference estimates of the percentage change from baseline with 95% confidence intervals.
- Treatment with ERN/LRPT produced significantly greater improvements in Lp(a), ApoB, non–HDL–C, ApoA1, and ApoB/ApoA1 ratio compared with placebo/active comparator in each study.
- These effects were generally consistent across key subgroups within each study.